There are several types of GLP medications that engage different types of glucagon receptors, giving them different effects in different people: Single receptor agonists (GLP-1 only): Ozempic, Wegovy, Saxenda Dual receptor agonists (GLP-1 + GIP): Mounjaro, Zepbound Triple receptor agonists (GLP-1 + GIP + glucagon): in development early studies show even greater metabolic effects These medications are changing how we are able to ameliorate obesity, food addiction, insulin resistance, and cardiometabolic risks
So far, Eli Lilly and Hanmi Pharmaceuticals are the only companies so far pursuing clinical trials of triple agonists
The metabolic effects of tirzepatide interact with the hormonal environment created by estrogen, progesterone, and testosterone replacement
Sermorelin is a 29-amino acid peptide that works by stimulating your pituitary gland to produce and release growth hormone naturally
The answer was no, or close enough to no that it would not be useful as a medicine